Johnson & Johnson’s (JNJ) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $215.00 target price on the stock.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a neutral rating on the stock in a report on Friday, July 19th. Bank of America cut their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a neutral rating on the stock in a report on Wednesday, April 17th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an equal weight rating in a report on Thursday, July 18th. TD Cowen cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a buy rating on the stock in a report on Thursday, July 18th. Finally, Royal Bank of Canada restated an outperform rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of Moderate Buy and a consensus price target of $173.21.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $2.28 during trading hours on Monday, reaching $158.97. 7,595,322 shares of the company were exchanged, compared to its average volume of 7,396,974. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The stock’s fifty day moving average is $150.02 and its two-hundred day moving average is $153.09. The company has a market cap of $382.59 billion, a price-to-earnings ratio of 9.98, a P/E/G ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.12%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Institutional Investors Weigh In On Johnson & Johnson

Several large investors have recently made changes to their positions in JNJ. Caprock Group LLC grew its position in Johnson & Johnson by 50.5% in the second quarter. Caprock Group LLC now owns 69,987 shares of the company’s stock valued at $10,229,000 after purchasing an additional 23,492 shares in the last quarter. Orca Investment Management LLC grew its position in Johnson & Johnson by 0.5% in the second quarter. Orca Investment Management LLC now owns 19,290 shares of the company’s stock valued at $2,819,000 after purchasing an additional 89 shares in the last quarter. W Advisors LLC grew its position in Johnson & Johnson by 0.8% in the second quarter. W Advisors LLC now owns 9,036 shares of the company’s stock valued at $1,321,000 after purchasing an additional 72 shares in the last quarter. Lynch & Associates IN grew its position in Johnson & Johnson by 2.6% in the second quarter. Lynch & Associates IN now owns 91,451 shares of the company’s stock valued at $13,366,000 after purchasing an additional 2,293 shares in the last quarter. Finally, Anchor Capital Advisors LLC grew its position in Johnson & Johnson by 1.5% in the second quarter. Anchor Capital Advisors LLC now owns 126,947 shares of the company’s stock valued at $18,555,000 after purchasing an additional 1,924 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.